Cellectar Biosciences (CLRB) Long-Term Investments (2017 - 2024)
Cellectar Biosciences (CLRB) posted Long-Term Investments of $23566.0 for Q1 2024, little changed sequentially from $23566.0 in Q4 2023, and down 62.72% YoY from $63217.0 in Q2 2023.
Cellectar Biosciences (CLRB) Long-Term Investments (2017 - 2024) Analysis & Trends
Cellectar Biosciences has reported Long-Term Investments for 8 years, with the latest figure at $23566.0 in Q1 2024.
- Quarterly Long-Term Investments fell 62.72% year-over-year to $23566.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $23566.0 (down 62.72% YoY) and the FY2023 annual result came in at $23566.0, down 68.58% from the prior year.
- Long-Term Investments steadied at $23566.0 in Q1 2024 per CLRB's latest filing, from $23566.0 in the prior quarter.
- Over five years, Long-Term Investments peaked at $219121.0 in Q3 2020 and troughed at $23566.0 in Q2 2023.
- A 5-year average of $72510.1 and a median of $75000.0 in 2020 frame the typical range for Long-Term Investments.
- The widest YoY moves for Long-Term Investments: up 192.16% in 2020, down 84.98% in 2020.
- Over 5 years, Long-Term Investments stood at $75000.0 in 2020, then changed by 0.0% to $75000.0 in 2021, then changed by 0.0% to $75000.0 in 2022, then tumbled by 68.58% to $23566.0 in 2023, then changed by 0.0% to $23566.0 in 2024.
- According to Business Quant data, Long-Term Investments over the past three periods registered $23566.0, $23566.0, and $23566.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 23,566.00 |
| Dec 31, 2023 | 23,566.00 |
| Sep 30, 2023 | 23,566.00 |
| Jun 30, 2023 | 23,566.00 |
| Mar 31, 2023 | 63,217.00 |
| Dec 31, 2022 | 75,000.00 |
| Sep 30, 2022 | 81,214.00 |
| Jun 30, 2022 | 81,214.00 |
| Mar 31, 2022 | 81,214.00 |
| Dec 31, 2021 | 75,000.00 |
| Sep 30, 2021 | 75,000.00 |
| Jun 30, 2021 | 75,000.00 |
| Mar 31, 2021 | 75,000.00 |
| Dec 31, 2020 | 75,000.00 |
| Sep 30, 2020 | 219,121.00 |
| Jun 30, 2020 | 81,214.00 |
| Mar 31, 2020 | 81,214.00 |
| Dec 31, 2019 | 75,000.00 |
| Sep 30, 2019 | 75,000.00 |
| Jun 30, 2019 | 75,000.00 |